PE20120654A1 - Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona - Google Patents

Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona

Info

Publication number
PE20120654A1
PE20120654A1 PE2011001611A PE2011001611A PE20120654A1 PE 20120654 A1 PE20120654 A1 PE 20120654A1 PE 2011001611 A PE2011001611 A PE 2011001611A PE 2011001611 A PE2011001611 A PE 2011001611A PE 20120654 A1 PE20120654 A1 PE 20120654A1
Authority
PE
Peru
Prior art keywords
diona
dioxopiperidin
isoindolin
formulations
amino
Prior art date
Application number
PE2011001611A
Other languages
English (en)
Inventor
Anthony Tutino
Michael T Kelly
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42635489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120654(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of PE20120654A1 publication Critical patent/PE20120654A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)

Abstract

REFERIDA A UNA FORMA DE DOSIFICACION ORAL QUE COMPRENDE: 1) POMALIDOMIDA O UNA SAL O SOLVATO FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, EN UNA CANTIDAD QUE PROPORCIONA 0.5 mg-4 mg DE POTENCIA DE POLIDOMIDA; B) UN PORTADOR O EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE SELECCIONADO DE ALMIDON PREGELATINIZADO, ESTEARILFUMARATO DE SODIO, MANITOL, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE CANCER, DOLOR, TRASTORNO PULMONAR, ENFERMEDAD PARASITICA, ENTRE OTROS
PE2011001611A 2009-05-19 2010-05-19 Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona PE20120654A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17967809P 2009-05-19 2009-05-19

Publications (1)

Publication Number Publication Date
PE20120654A1 true PE20120654A1 (es) 2012-05-31

Family

ID=42635489

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001611A PE20120654A1 (es) 2009-05-19 2010-05-19 Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona

Country Status (34)

Country Link
US (6) US8828427B2 (es)
EP (3) EP3199149A1 (es)
JP (1) JP5752677B2 (es)
KR (1) KR101381060B1 (es)
CN (3) CN105640918A (es)
AU (1) AU2010249615B2 (es)
BR (1) BRPI1007855B1 (es)
CA (1) CA2752550C (es)
CL (1) CL2011001969A1 (es)
CO (1) CO6430422A2 (es)
CR (1) CR20110435A (es)
CY (2) CY1118632T1 (es)
DK (2) DK3351240T3 (es)
EC (1) ECSP11011317A (es)
ES (2) ES2728776T3 (es)
HR (2) HRP20170179T1 (es)
HU (2) HUE043862T2 (es)
IL (2) IL214644A (es)
LT (2) LT3351240T (es)
MX (2) MX342330B (es)
NI (1) NI201100158A (es)
NZ (1) NZ594557A (es)
PE (1) PE20120654A1 (es)
PH (1) PH12015501523A1 (es)
PL (2) PL2391355T3 (es)
PT (2) PT3351240T (es)
RU (1) RU2479307C1 (es)
SG (1) SG174137A1 (es)
SI (2) SI3351240T1 (es)
SM (1) SMT201700097B (es)
TR (1) TR201905423T4 (es)
UA (1) UA102582C2 (es)
WO (1) WO2010135396A2 (es)
ZA (1) ZA201105962B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
AU2010249615B2 (en) 2009-05-19 2013-07-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
US9968627B2 (en) 2013-03-26 2018-05-15 Celgene Corporation Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
AU2014248263A1 (en) * 2013-04-02 2015-10-15 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
US20150045391A1 (en) * 2013-08-08 2015-02-12 Array Biopharma Inc Filanesib combined with pomalidomide displays enhanced anti-tumor activity
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
HUE061382T2 (hu) 2014-08-22 2023-06-28 Celgene Corp Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
CN104523692A (zh) * 2014-12-16 2015-04-22 南京艾德凯腾生物医药有限责任公司 一种泊马度胺复合物及其制备方法
PT3313528T (pt) 2015-06-29 2021-09-16 Bristol Myers Squibb Co Regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do cancro
CN105213392A (zh) * 2015-09-29 2016-01-06 浙江大学 泊马度胺在制备减轻多发性硬化症的药物中的应用
WO2018013689A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
WO2018013693A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
EP3493791A1 (en) * 2016-08-02 2019-06-12 Synthon B.V. Pharmaceutical composition comprising pomalidomide
WO2018150435A1 (en) * 2017-02-18 2018-08-23 Natco Pharma Limited Pharmaceutical compositions of pomalidomide
US10093647B1 (en) * 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
JP2020533383A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 癌の組合せ治療
US10093649B1 (en) * 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en) * 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
CN107982216A (zh) * 2017-12-08 2018-05-04 佛山市弘泰药物研发有限公司 一种泊马度胺自微乳制剂及其制备方法
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
EP3545949A1 (en) * 2018-03-29 2019-10-02 Midas Pharma GmbH Oral dosage forms comprising pomalidomide crystalline form a
CN112312904A (zh) 2018-04-16 2021-02-02 C4医药公司 螺环化合物
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
MX2022012964A (es) 2020-04-15 2022-11-09 Tecnimede Soc Tecnico Medicinal Sa Forma de dosificacion oral solida que comprende pomalidomida.
EP3900701A1 (en) 2020-04-22 2021-10-27 Lotus Pharmaceutical Co., Ltd. Composition of pomalidomide for oral dosage form
WO2023062647A1 (en) * 2021-10-12 2023-04-20 Reliance Life Sciences Pvt.Ltd. Pomalidomide formulation
EP4233849A1 (en) 2022-02-25 2023-08-30 KRKA, d.d., Novo mesto Pharmaceutical composition comprising pomalidomide
CN118108655B (zh) * 2024-04-23 2024-06-28 四川大学华西医院 一类异吲哚啉-1,3-二酮衍生物、其制备方法、其用途和含该衍生物的药物组合物

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US555939A (en) * 1896-03-10 Device for opening sealed packages
US3145146A (en) 1961-10-31 1964-08-18 Warner Lambert Pharmaceutical Modified mannitol for pharmaceutical tablets
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
JPS601128A (ja) 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
JPS6396126A (ja) 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
US5974203A (en) 1988-04-11 1999-10-26 Canon Kabushiki Kaisha Pattern recognition communication apparatus for transmitting and receiving image data
WO1992014455A1 (en) 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5594637A (en) 1993-05-26 1997-01-14 Base Ten Systems, Inc. System and method for assessing medical risk
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
JPH10508131A (ja) 1994-10-28 1998-08-04 アドバンスド・ヘルス・メド・イー・システムズ コーポレーション 処方箋管理システム
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5619991A (en) 1995-04-26 1997-04-15 Lucent Technologies Inc. Delivery of medical services using electronic data communications
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
JPH0977669A (ja) 1995-09-19 1997-03-25 Takeda Chem Ind Ltd ビタミンb群顆粒品の組成物およびその製造方法
US5832449A (en) 1995-11-13 1998-11-03 Cunningham; David W. Method and system for dispensing, tracking and managing pharmaceutical trial products
US6063026A (en) 1995-12-07 2000-05-16 Carbon Based Corporation Medical diagnostic analysis system
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
EP0925294B3 (en) 1996-07-24 2018-07-04 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5924074A (en) 1996-09-27 1999-07-13 Azron Incorporated Electronic medical records system
US6131090A (en) 1997-03-04 2000-10-10 Pitney Bowes Inc. Method and system for providing controlled access to information stored on a portable recording medium
WO1999010829A1 (en) 1997-08-22 1999-03-04 Deka Products Limited Partnership Health care system and method for physician order entry
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6376545B1 (en) 1998-11-10 2002-04-23 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing L-DOPA ethyl ester
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9904585D0 (en) 1999-02-26 1999-04-21 Gemini Research Limited Clinical and diagnostic database
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6202923B1 (en) 1999-08-23 2001-03-20 Innovation Associates, Inc. Automated pharmacy
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
AU1928501A (en) 1999-11-24 2001-06-04 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
DE60130799T2 (de) 2000-11-30 2008-07-17 Children's Medical Center Corp., Boston Synthese von 4-aminothalidomid enantiomeren
WO2002043704A1 (en) 2000-12-01 2002-06-06 Kyowa Hakko Kogyo Co., Ltd. Composition improved in solubility or oral absorbability
US20020128228A1 (en) 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
CN1511420A (zh) 2001-11-09 2004-07-07 松下电器产业株式会社 运动图像编码方法和装置
JP4027693B2 (ja) 2002-03-20 2007-12-26 トリニティ工業株式会社 塗料送給装置及びバルブユニット
WO2003086373A1 (en) * 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US7230012B2 (en) 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US20040191298A1 (en) 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2005051350A2 (en) 2003-10-28 2005-06-09 Torrent Pharmaceuticals Limited Water dispersible tablet
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP1694328A4 (en) 2003-12-02 2010-02-17 Celgene Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
GB0400993D0 (en) 2004-01-16 2004-02-18 Norton Healthcare Ltd Stable gabapentin compositions
NZ550026A (en) 2004-03-22 2009-10-30 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
CA2563810A1 (en) 2004-04-23 2005-11-10 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
WO2006053160A2 (en) 2004-11-12 2006-05-18 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
CA2588597A1 (en) 2004-11-23 2006-06-01 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
US10130624B2 (en) 2005-03-15 2018-11-20 Lupin Limited Pharmaceutical compositions of amlodipine and benazepril
ES2633088T3 (es) 2005-05-18 2017-09-19 Sumitomo Dainippon Pharma Co., Ltd. Comprimido estable que contiene droxidopa
AU2006250340C1 (en) 2005-05-26 2014-06-12 Sumitomo Pharma Co., Ltd. Pharmaceutical composition
JP2007028086A (ja) 2005-07-14 2007-02-01 Funai Electric Co Ltd リモコン装置
US8715677B2 (en) 2005-09-01 2014-05-06 Celgene Corporation Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
ZA200805795B (en) * 2005-12-29 2009-10-28 Celgene Corp Methods for treating cutaneous lupus using aminoisoindoline compounds
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2712724A1 (en) 2008-01-29 2009-08-06 Celgene Corporation Use of lenalidomide or pomalidomide for treating a disease associated with cd59 deficiency
AU2010249615B2 (en) 2009-05-19 2013-07-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione

Also Published As

Publication number Publication date
CN102333525A (zh) 2012-01-25
NZ594557A (en) 2013-07-26
PT3351240T (pt) 2019-06-21
JP2012526855A (ja) 2012-11-01
SMT201700097B (it) 2017-03-08
WO2010135396A3 (en) 2011-09-15
ES2615511T3 (es) 2017-06-07
HUE033115T2 (en) 2017-11-28
AU2010249615A1 (en) 2011-09-08
AU2010249615B2 (en) 2013-07-18
US20180325885A1 (en) 2018-11-15
US20200222382A1 (en) 2020-07-16
IL214644A0 (en) 2011-11-30
EP2391355B1 (en) 2017-01-18
IL241949A0 (en) 2015-11-30
DK2391355T3 (en) 2017-02-27
DK3351240T3 (da) 2019-06-17
MX2011008554A (es) 2011-10-06
LT2391355T (lt) 2017-03-10
RU2479307C1 (ru) 2013-04-20
US10555939B2 (en) 2020-02-11
US8828427B2 (en) 2014-09-09
KR101381060B1 (ko) 2014-04-11
ES2728776T3 (es) 2019-10-28
CY1122064T1 (el) 2020-11-25
IL241949A (en) 2017-08-31
IL214644A (en) 2015-10-29
BRPI1007855A2 (pt) 2016-02-23
ECSP11011317A (es) 2011-10-31
EP2391355A2 (en) 2011-12-07
CL2011001969A1 (es) 2012-07-20
ZA201105962B (en) 2012-11-28
PH12015501523A1 (en) 2015-09-21
NI201100158A (es) 2012-01-24
US20110045064A1 (en) 2011-02-24
RU2011134499A (ru) 2013-02-27
LT3351240T (lt) 2019-06-10
EP3351240A1 (en) 2018-07-25
WO2010135396A2 (en) 2010-11-25
SI2391355T1 (sl) 2017-07-31
CN105640918A (zh) 2016-06-08
US20140336223A1 (en) 2014-11-13
KR20120014114A (ko) 2012-02-16
CO6430422A2 (es) 2012-04-30
US20210085665A1 (en) 2021-03-25
US9993467B2 (en) 2018-06-12
CA2752550A1 (en) 2010-11-25
HRP20170179T1 (hr) 2017-04-07
MX342330B (es) 2016-09-26
EP3199149A1 (en) 2017-08-02
UA102582C2 (en) 2013-07-25
PT2391355T (pt) 2017-02-21
EP3351240B1 (en) 2019-04-10
HRP20191094T1 (hr) 2019-09-20
BRPI1007855B1 (pt) 2020-03-10
TR201905423T4 (tr) 2019-05-21
SI3351240T1 (sl) 2019-08-30
PL2391355T3 (pl) 2017-05-31
CR20110435A (es) 2012-01-06
PL3351240T3 (pl) 2019-09-30
SG174137A1 (en) 2011-10-28
CY1118632T1 (el) 2017-07-12
CA2752550C (en) 2014-07-15
JP5752677B2 (ja) 2015-07-22
US20160206607A1 (en) 2016-07-21
CN106176662A (zh) 2016-12-07
HUE043862T2 (hu) 2021-12-28

Similar Documents

Publication Publication Date Title
PE20120654A1 (es) Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona
ES2526648T3 (es) Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
PE20210401A1 (es) Composiciones farmaceuticas que comprenden meloxicam
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
AR070731A1 (es) Composicion farmaceutica para farmacos poco solubles
ECSP066807A (es) Formulaciones galénicas de compuestos orgánicos
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
PE20140099A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
ECSP088240A (es) Composición de trazodona para administración una vez por día
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
PA8591701A1 (es) Derivados de pirrolopirimidina
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
PE20081799A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
AR062393A1 (es) Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
AR080096A1 (es) Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
CO6640318A2 (es) Formas de dosificación oral de bendamustina
CR8172A (es) Saquinavir mesilato en forma de dosificacion farmaceutica oral
BR112013006651A2 (pt) composição e cocristal de aprepitante l-prolina
ECSP12011627A (es) Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st

Legal Events

Date Code Title Description
FG Grant, registration